| Revenue growth | Q2 -11.4% YoY; H1 +35.6% YoY |
|---|---|
| Margins | Q2 EBITDA 22.9% (-754bps); H1 30.3% (+594bps) |
| Order book | 99 active CMS projects vs 98 in Q2FY26 |
| Demand visibility | Growth in new project orders; strong RFP activity |
| Management confidence | CEO: growth expectations remain intact |
Growth
Q2 income -11.4% YoY; H1 +35.6%. Q2 PAT -47.0%; H1 PAT +80.2%. H1 EBITDA +68.6%.
Outlook
No numeric guidance; CEO says growth expectations intact for FY27 and next year. Rs261 Cr capex on R&D and peptides.
Risks
Sharp Q2 margin compression from operating deleverage; CEO concedes a Q2 performance dip.
Last quarter's promises, checked
Delivered
- 25%+ EBITDA margin (long-term, H1 basis) → H1 EBITDA margin 30.3% (= BEAT)
Partly delivered
- ~20% annual growth aspiration for FY27/FY28 → H1 income +35.6% YoY, Q2 income -11.4% YoY (= PARTIAL)
Missed
- 25%+ EBITDA margin (long-term) → Q2 EBITDA margin 22.9% (= MISS)
Investor Presentation filed with NSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹19,424.00
- Market cap
- ₹24,921 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 50.1×Sector 47.2×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
Neuland Laboratories Q2 FY27 Results: Net Profit ₹51.6 Cr, Down 46.7% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹449.7 Cr (-12.6% YoY) and net profit of ₹51.6 Cr (-46.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.6 Cr · -46.7% YoY
Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Neuland Laboratories Business Update
Neuland Laboratories' Unit 3 manufacturing facility received an Establishment Inspection Report from the US FDA. The agency has officially closed the inspection.
Neuland Laboratories Other Announcement
Neuland Laboratories Ltd has submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Regulation 31.